NovoArc GmbH
PrivateLast Round
Seed
Dec 9, 2024
Total Funding Raised
$1.2M
Company Overview
NovoArc GmbH is a biotechnology company that develops and manufactures lipid-based formulations to enable the oral delivery of drugs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Advanced Materials, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NovoArc GmbH Comparables
Compare NovoArc GmbH with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Particella | 81% | |
| Intract Pharma | 79% | |
| ACM Biolabs | 77% | |
NovoArc GmbH Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Dec 9, 2024 | ||||
| Seed | Feb 1, 2022 |
NovoArc GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Austria Wirtschaftsservice | Grant, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 9, 2024
$960K round led by Austria Wirtschaftsservice
- Feb 1, 2022
Completed a Seed funding round.
NovoArc GmbH Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NovoArc GmbH's valuation, stock price, and market status.